Big Pharma stocks are core holdings for many investors. You might even have one or two in your own portfolio. If you do, I’m sorry to say I have bad news for you.
Drug stocks are facing major challenges in 2011.
For years, drug stocks like Pfizer (PFE), Johnson & Johnson (JNJ), Merck (MRK), and Eli Lilly (LLY) have posted steady double-digit earnings growth. Many of them have also provided a steady stream of income through regular dividends.
Permalink: [609] Top Stocks To Buy – Drug Stocks Crumbling… What To Do Now!
These two qualities have made drug stocks a staple in stock portfolios for decades.
Now, for the first time in a long while, many big name drug firms will see their growth rates slip into the single digits. Here’s why…
The biggest threat to earnings growth is also the hardest problem to solve. I’m talking about major revenue producing drugs losing their patent protection.
Drug stocks are facing major challenges in 2011.
For years, drug stocks like Pfizer (PFE), Johnson & Johnson (JNJ), Merck (MRK), and Eli Lilly (LLY) have posted steady double-digit earnings growth. Many of them have also provided a steady stream of income through regular dividends.
Permalink: [609] Top Stocks To Buy – Drug Stocks Crumbling… What To Do Now!
These two qualities have made drug stocks a staple in stock portfolios for decades.
Now, for the first time in a long while, many big name drug firms will see their growth rates slip into the single digits. Here’s why…
The biggest threat to earnings growth is also the hardest problem to solve. I’m talking about major revenue producing drugs losing their patent protection.
